NCT06196255View on ClinicalTrials.gov

Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2028

Conditions
Multiple Myeloma
Interventions
DRUG

anti-FcRL5 CAR-T

anti-FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.

Trial Locations (1)

221006

RECRUITING

The affiliated hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors
lead

Xuzhou Medical University

OTHER